Investigating platelet transfusion thresholds for extremely preterm infants
1/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)
This study is looking at the best way to give platelet transfusions to very premature babies born between 23 and 26 weeks to help prevent serious bleeding and improve their chances of survival during their first week in the hospital.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10866100 on NIH RePORTER |
What this research studies
This research focuses on extremely preterm infants born between 23 to 26 weeks of gestation, who are at high risk for bleeding and thrombocytopenia. The study aims to determine the optimal platelet transfusion threshold to minimize the risk of severe bleeding and mortality in these vulnerable infants during their first week of life. By comparing lower and higher transfusion thresholds, the research seeks to clarify the best practices for platelet transfusions in neonatal intensive care units (NICUs). The approach involves a multicenter trial where infants will be monitored for outcomes related to bleeding and survival based on the transfusion thresholds used.
Who could benefit from this research
Good fit: Ideal candidates for this research are extremely preterm infants born at 23 to 26 weeks gestation who are admitted to the NICU.
Not a fit: Patients who are not extremely preterm or those who do not require platelet transfusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced complications for extremely preterm infants.
How similar studies have performed: Previous research has shown promising results with lower platelet transfusion thresholds in similar populations, indicating potential for significant advancements in care.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Patel, Ravi Mangal — Emory University
- Study coordinator: Patel, Ravi Mangal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.